uridine diphosphate glucose

Uridine diphosphate glucose (UDP-glucose) is a pyrimidine nucleotide sugar, serving as a precursor for oligosaccharides, polysaccharides, glycoproteins, and glycolipids containing glucose. It is a key intermediate in carbohydrate metabolism and participates in numerous enzymatic reactions, acting as a P2Y14 agonist.

Dapagliflozin-3-O-β-D-glucuronide is a metabolite of dapagliflozin . Dapagliflozin is a first generation selective sodium glucose cotransporter (SGLT) 2 inhibitor that blocks glucose transport.[1] Dapagliflozin is metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A9 to dapagliflozin-3-O-β-D-glucuronide, which is 2,600-fold less potent than the parent compound with regard to SGLT2 inhibition.[2]

yGsy2p-IN-H23 is a potent, first-in-class inhibitor specifically designed to target yeast glycogen synthase 2 (yGsy2p). It demonstrates an IC50 value of 875 μM for human glycogen synthase 1 (hGYS1). This compound binds precisely within the uridine diphosphate glucose (UDPG) binding pocket of yGsy2p. Its utilization in research primarily focuses on studying glycogen storage diseases (GSDs).

T4 Phage β-glucosyltransferase is a DNA-modifying enzyme encoded by T4 phage, which facilitates the transfer of glucose from uridine diphosphate glucose to the 5-hydroxymethylcytosine bases in phage T4 DNA.

Uridine diphosphate glucuronic acid (UDP-GlcA) trisodium is a cofactor formed by the catalytic activity of UDP-glucose dehydrogenase. It contains an Azide group, enabling it to undergo copper-catalyzed azide-alkyne cycloaddition reactions (CuAAc) with molecules that have Alkyne groups. Additionally, it can participate in strain-promoted azide-alkyne cycloaddition reactions (SPAAC) with molecules containing DBCO or BCN groups.